COSMO PHARMACEUTICALS

Clascoterone, a new acne treatment, is available in the US but not yet in Europe. It targets hormonal causes of acne without significant side effects, but its effectiveness compared to existing treatments is unclear. Cosmo Pharmaceuticals, the producer, is seeking distribution partners globally, citing the pandemic as a delay factor.

Yosi Health appoints Lori Ryan as Director of Customer Success and Patrick McInnis as VP of Partnerships. Precision for Medicine hires Margaret Keegan as CEO, succeeding Mark Clein as Executive Chairman. Cosmo Pharmaceuticals names Egle Gedrimaite Head of Global Business Development. Sumitomo Pharma America appoints Kenton Stewart as its first CCO. IGM elevates Mary Beth Harler to CEO. Pangea Biomed adds Dr. Kenneth D. Aldape to its scientific advisory board. Johnson & Johnson, Bayer, Pfizer, and CVS Health announce layoffs.

The digital health market, valued at $180.2 billion in 2023, is expected to grow to $549.7 billion by 2028, driven by technologies like mHealth, telehealth, and digital therapeutics. Key players include DexCom and Teladoc Health, with the US market leading at $88 billion in 2023. Telemedicine and wearable devices are pivotal, with the telemedicine market projected to reach $286.22 billion by 2030. Precision medicine and medical imaging technologies are also transforming healthcare, with companies like Merck & Co., Sanofi, and AstraZeneca leading in innovation and growth.

Medtronic plc expands its partnership with Cosmo Intelligent Medical Devices, investing $100 million upfront and offering royalties for AI-driven endoscopic care advancements. This collaboration aims to enhance GI GeniusTM's capabilities, leveraging AI AccessTM for scalable healthcare solutions, focusing on improving patient outcomes and diagnostic tools in gastrointestinal care.

Medical device companies are increasingly adopting AI for therapeutic and diagnostic applications, enhancing disease detection and treatment. Medtronic is investing in AI, partnering with NVIDIA and Cosmo Pharmaceuticals for its GI Genius module, and expanding its Hugo robotic system. AI in cancer diagnostics is growing, with a market expected to reach a 28.0% CAGR by 2030. Henry Schein integrates AI into Dentrix Ascend for improved dental care.